Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York City
Members of Jaguar’s management team along with third-party key opinion
leaders will host a series of presentations beginning at
Space for the event is limited and advanced registration is required. Analysts and institutional investors interested in attending the event should contact Allison Soss at email@example.com to register.
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s intention to develop species-specific formulations of Neonorm™ in six additional target species, and Jaguar’s planned development of formulations of Canalevia™ for cats, horses, and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.